Why Genetic Technologies (GENE) Stock Is Spiking Today

NEW YORK (TheStreet) -- Genetic Technologies (GENE) shares are up 13.2% to $1.16 on Monday after the company announced that the number of BREVAGen breast cancer risk test samples it received this quarter was up 37% over the previous quarter.

The company more than doubled the number of samples it received -- 3,935 compared to 1,547 -- for the fiscal year ending June 30 than it did the previous fiscal year.

The test is a cheek swab was introduced in the U.S. in 2012 that upon completion is sent to Genetic Technologies for analysis.

Must ReadWarren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

5 Stocks Under $10 Set to Soar

5 Stocks Ready for Breakouts

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Stalking an Entry in RetailMeNot

Stalking an Entry in RetailMeNot